ATLAS: Week 48 Results From Phase III Study of Switching to Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Patients With No Prior Virologic Failure

March 4-7, 2019; Seattle, Washington
Switch to long-acting dual therapy regimen maintains virologic suppression at Week 48.
Format: Microsoft PowerPoint (.ppt)
File Size: 177 KB
Released: March 9, 2019

Acknowledgements

Directly provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This program is supported by independent educational grants from
Gilead Sciences
Janssen Therapeutics
Merck & Co., Inc.
ViiV Healthcare

Related Content

Drs. Jean Rene Anderson and William Short speak to the balancing act when considering HIV treatments during pregnancy, from Clinical Care Options (CCO)

Jean Rene Anderson, MD William R. Short, MD, MPH, AAHIVS Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: August 12, 2022 Expired: August 11, 2023

Clinical Care Options (CCO) commentary from Dr Darrell Tan on the dosing options for long-acting injectable cabotegravir plus rilpivirine for HIV treatment

Babafemi Taiwo, MBBS
Program Director
Darrell H. S. Tan, MD, FRCPC, PhD
Released: August 12, 2022

Safety and efficacy of broadly neutralizing antibody VRC01 with early ART in infants with HIV, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 5, 2022

Opciones de cuidado clínico (CCO) presenta a la Dra. Alicia Piñeirúa que explica los principales factores que hay que tener en cuenta a la hora de optimizar el tratamiento antirretroviral en el marco de la supresión viral en pacientes que viven con el VIH y la osteopenia

person default Alicia Piñeirúa Menéndez, MD, MPH Released: August 2, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings